



#### Disclosures

I receive a monthly retainer as a part time (3 days / month) senior advisor for **Health Catalyst**. I also own (a small amount of) Health Catalyst stock.

Other than that, neither I nor any family members have any relevant financial relationships to be directly or indirectly discussed, referred to or illustrated within the presentation, with or without recognition.



## The core problem / opportunity:

#### Clinical variation



### Four main subtypes of clinical variation

- 1. Massive variation in clinical practices (impossible that all, or even most, patients receive good care)
- 2. High rates of inappropriate care (risk of harm inherent in the treatment outweighs any potential benefit)
- 3. Preventable care-associated injury and death (patient safety)
- 4. Striking inability to "consistently do what we know works" (high reliability care)



#### Variation translates into waste

## **30-50+%** of all health care resource expenditures are

#### quality-associated waste:

- recovering from preventable foul-ups
- building unusable products
- providing unnecessary treatments
- simple inefficiency



### Some viable estimates suggest

as much as 65% of all care delivery spending is quality-associated waste.

In 2020, that's as much as \$2 trillion in financial opportunity;

10 to 100 times greater than opportunities associated with traditional revenue models

Follow the money!!



### Quality is <u>not</u> free (Phil Crosby was waxing poetic)

## It always requires investment

- change leadership (time and thought),
- study and investigation,
- data systems,
- physical plant, equipment ...

it's just that it has a

massive return on investment (ROI)



## MUCH higher ROI from waste elimination than from revenue growth

Revenue growth:

5 to 9% contribution

for each case added

Net
Operating
Margin
(and return on investment)

Waste elimination:

50 to >100% contribution

for each case avoided



## Quality waste has a nested structure

	Waste class	% of all waste	Waste subclasses
3.	Case-rate utilization (# cases per population)	45%	<ul> <li>a) Inappropriate cases (risk outweighs benefit) (e.g., many cath lab procedures; CTPA)</li> <li>b) Preference-sensitive cases (when given a fair choice, many patients opt out) (e.g., elective hips, knees; end-of-life care)</li> <li>c) Avoidable cases (hot spotting; move upstream) (e.g., team-based care)</li> </ul>
2.	Within-case utilization (# and type of units per case)	1 40%	a) Clinical variation (e.g., QUE studies; surgical equipment) b) Avoidable patient injuries (e.g., serious safety event systems; CLABSI)
1.	Efficiency (cost per unit of care)	15%	a) Supply chain b) Administrative inefficiencies - regulatory burden - billing thrash - TPS Lean observation - current EMR function



## Financial alignment under different payment mechanisms

#### PAYMENT METHOD

WASTE REMOVAL LEVEL % of all waste

FFS

Per Provider case at risk

3. Case-rate utilization

(# cases per population)

45%

V

V



2. Within-case utilization

(# and type of units per case)

40%

V



1. Efficiency

(cost per unit of care)

15%



Note: For green arrows, savings from waste elimination accrue to the care delivery organization; for red arrows, savings go to payer organizations.



## Financial alignment

#### Who makes the investment?

(always a care delivery group – it is <u>clinical</u> change)

versus


## Who gets the waste savings?

(depends on type of waste, versus payment mechanism)

## There are proven, viable ways to address this, even under fee-for-service

(coming later in the series)

## Financial impact of improving quality and reducing waste at one system



James Brent C and Poulsen Gregory P. The case for capitation: It's the only way to cut waste while improving quality. *Harv Bus Rev* 2016; 94(7-8):102-11, 134 (Jul-Aug).



#### Given that framework,

#### What does the future hold?

Walter Gretzky (Wayne Gretzky's father):

Skate to where the puck is going to be, not where it has been.




# "Pay for value" continues to grow Forward looking indicators:

- > Kaiser Permanente (continued rapid growth within existing geographic markets, mostly)
- ➤ Medicare Advantage (continued rapid growth)

  ACOs (Leavitt Partners; mostly commercial)



#### Medicare trends over time





## "Pay for value" continues to grow

#### Forward looking indicators:

- ➤ Kaiser Permanente (continued rapid growth within existing geographic markets, mostly)
- ➤ Medicare Advantage (continued rapid growth)

  ACOs (Leavitt Partners; mostly commercial)
- > ERISA direct to provider contracting
  (11% of large employers, according to Modern Healthcare)



## "Pay for value" continues to grow

#### Forward looking indicators:

- ➤ Kaiser Permanente (continued rapid growth within existing geographic markets, mostly)
- ➤ Medicare Advantage (continued rapid growth)

  ACOs (Leavitt Partners; mostly commercial)
- > ERISA direct to provider contracting
  (11% of large employers, according to Modern Healthcare)
- > Provider-payer consolidation (vertical alignment)
  by ownership or partnership (e.g., UPMC; United Healthcare; HPH /
  Queens Health Systems partnerships with HMSA)



### Implications – we will see:

- Increasing focus on waste elimination through "move upstream" strategies: primary care-based population health and clinical variation control using clinical decision support tools (a.k.a. clinical knowledge management = "learning healthcare systems")
- Care delivery organizations will increasingly seek capitated risk through ownership or partnership (role of health insurance organizations changes dramatically)
- Stand-alone specialty care practices and hospitals become "price takers" – intense competition mainly around payment rates



## Better has no limit ...

an old Yiddish proverb